Stoke Therapeutics (STOK) Cash from Operations (2018 - 2026)

Stoke Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 60582000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 145.96% year-over-year to 60582000.0 in Q1 2026; TTM through Mar 2026 was 146824000.0, a 311.13% decrease from a year earlier, with the FY2025 full-year figure at 45585000.0, up 152.49% from the prior year.
• Cash from Operations slipped to 60582000.0 in Q1 2026 per STOK's latest filing, from 30454000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 131827000.0 in Q1 2025 and bottomed at 60582000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 21800000.0 (2023), against an average of 12634176.47.
• Across the five-year window, Cash from Operations sank 165.73% in 2023 and jumped 636.62% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 22373000.0 in 2022, then increased by 7.71% to 20649000.0 in 2023, then fell by 12.32% to 23193000.0 in 2024, then tumbled by 31.31% to 30454000.0 in 2025, then tumbled by 98.93% to 60582000.0 in 2026.
• Per Business Quant, the three latest STOK Cash from Operations figures stand at 60582000.0 (Q1 2026), 30454000.0 (Q4 2025), and 30366000.0 (Q3 2025).